

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

October 2012
Volume 15, Number 10

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – CON Protocol Code Project: Audit Results for OSCAR Submissions
- **Continuing Professional Development** – NOPS 2012, Annual Cancer Conference 2012
- **List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts** – Revised:
BRAVDOC, BRAVDOC7, BRLACD, BRLAACDT, UCNBEV, GICART, GICPART, GIFOLFIRI, GIFUC, UGIGAJCC, GIGAVECF, SAAVGEMD, SCHYPCAL
- **Website Resources and Contact Information**

EDITOR'S CHOICE

CON PROTOCOL CODE PROJECT: AUDIT RESULTS FOR OSCAR SUBMISSIONS

The BC Cancer Agency is pleased to share the results of its first audit of the claims submitted by the BC Communities Oncology Network (CON) sites via the OSCAR (Online System for Cancer drugs Adjudication and Reimbursement) system. The intent of the CON Protocol Code Project was previously highlighted in the [April 2012](#) and [July 2012](#) issues of the Systemic Therapy Update. As part of this initiative, the CON Protocol Code Project Team is performing a series of audits to assess the level of accuracy of protocol code submissions via OSCAR, and to assist community hospitals in achieving the desired target of 100% starting 01 January 2013.

Audit Description:

The following outcomes are evaluated at each level of the audit:

- Level 1
 - Presence of a protocol code with each OSCAR submission
- Level 2
 - Presence of an official BCCA protocol code for the drugs included for adjudication
- Level 3
 - Presence of an official BCCA protocol code that accurately reflects the patient's tumour site, disease stage and treatment intent

Audit Results:

The audit was conducted on claims submitted between the fiscal periods 1 to 5, 2012-2013. For all OSCAR submissions that successfully achieved level 1, at least 10% were randomly selected to validate level 3.

EDITOR'S CHOICE

Results from level 1 of the audit showed protocol code submission rates from the five BC health authorities varying widely from 0% to 90% (figure 1).




Figure 1. Percentage of protocol code submissions through OSCAR by BC health authority in periods 1 to 5, 2012-2013.

Overall, there was a significant improvement from periods 1 to 5 across all BC health authorities (7% to 35%) (figure 2), with one health authority demonstrating improvement in protocol submission rates from 37% to 90% (figure 1).




Figure 2. Percentage of protocol code submissions through OSCAR by all BC health authorities combined in periods 1 to 5, 2012-2013.

Analysis of the results from levels 2 and 3 of the audit are currently underway. Preliminary results are very promising, indicating that 91.4% of submissions were accurately coded according to the patient's tumour site, disease stage and treatment intent. Once these results are finalized, they will be presented to all BC community hospitals. Specific treatments and/or drugs that commonly pose protocol code

EDITOR'S CHOICE

selection challenges will be targeted for further evaluation.

It is important to note that the audit results are not intended for adjudicating OSCAR submissions for reimbursement, and no claim will be rejected based on these results. Rather, they are used to assist CON hospitals and health authorities in the accurate selection of protocol codes towards the target described above, and to guide the development of appropriate educational materials.

The BCCA Provincial Systemic Therapy Program and the CON Protocol Code Project Team would like to express thanks to the community hospitals for their efforts towards this project to date. The team continues to encourage users to contact the OSCAR Help Line at 1-888-355-0355 or by e-mail at oscar@bccancer.bc.ca for further questions regarding protocol codes and the project.

CONTINUING PROFESSIONAL DEVELOPMENT

UPCOMING CONFERENCES

National Oncology Pharmacy Symposium (NOPS) 2012:

Date: October 25-28, 2012

Location: Sheraton Cavalier, Saskatoon, SK

Website: www.capho.org/nops-2012

The theme of this year's conference is "*Patients First!*". Presentations will focus on patient safety, the changing landscape of drug review and access, the transition between oncology specialists and primary care providers, and effective communication.

2012 Annual Cancer Conference:

Date: November 29-December 1, 2012

Location: Westin Bayshore, Vancouver, BC

Website: www.bccanceragencyconference.com/index.htm

The theme of this year's conference is "*Evolving Dynamics in Research and Patient Care*". The program highlights areas of international, national, provincial and regional developments in research, clinical programs, medical and radiation oncology, technological innovations in services, telemedicine and telehealth, patient and societal engagement, predictive oncology and personalized treatments, and more.

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring “Compassionate Access Program” (previously Undesignated Indications Request) approval are prefixed with the letter “U”.

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVDOC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title updated to remove TAXOTERE[®] as a generic brand of DOCEtaxel is now available</i>	Palliative Therapy for Metastatic Breast Cancer Using DOCEtaxel
BRAVDOC7	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title updated to remove TAXOTERE[®] as a generic brand of DOCEtaxel is now available</i>	Palliative Therapy for Metastatic Breast Cancer Using Weekly DOCEtaxel
BRLAACD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title updated to remove TAXOTERE[®] as a generic brand of DOCEtaxel is now available</i>	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by DOCEtaxel
BRLAACDT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Title updated to remove TAXOTERE[®] as a generic brand of DOCEtaxel is now available</i>	Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide Followed by DOCEtaxel and Trastuzumab
UCNBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Information on lomustine and etoposide expanded; bevacizumab dosing schedule clarified</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab
GICART	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Mitomycin dose modified; Capecitabine length of treatment clarified; Renal dysfunction for mitomycin added</i>	Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
GICPART	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Capecitabine length of treatment clarified</i>	Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy
GIFOLFIRI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Folinic Acid (Leucovorin)
GIFUC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Added bilirubin and AST to baseline tests</i>	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer using Infusional Fluorouracil and CISplatin

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UGIGAJCC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation, Using CISplatin and Capecitabine
GIGAVECF	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment days clarified</i>	Palliative Therapy for Metastatic or Locally Advanced Gastric, Esophagogastric Cancer Using Epirubicin, CISplatin and Infusional 5-Fluorouracil
SAAVGEMD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Gemcitabine infusion rate clarified</i>	Second or Third Line Therapy for Soft Tissue Sarcomas using Gemcitabine and DOCEtaxel
SCHYPCAL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Calcium levels clarified</i>	Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
Cancer Drug Manual	www.bccancer.bc.ca/cdm
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 3028		sman3@bccancer.bc.ca
Provincial Systemic Therapy Program	604.877.707.5973		ldasilva2@bccancer.bc.ca
Communities Oncology Network (CON)	250.519.5501		jdenduyf@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 2638		nursinged@bccancer.bc.ca
Library/Cancer Information	888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 2623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Sally Man, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Johanna Den Duyf, MA
 Caroline Lohrisch, MD

Beth Morrison, MLS
 Lindsay Schwartz, RN, MScA
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)